International Clinical Psychopharmacology最新文献_第10页

Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders. 精神分裂症、情感分裂症和双相情感障碍患者的代谢综合征及其与抗精神病药物多药治疗的关系。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-02-13 DOI: 10.1097/yic.0000000000000538

Karim Abdel Aziz, Hind Mohd Ahmed, Emmanuel Stip, Dina Aly El-Gabry

{"title":"Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders.","authors":"Karim Abdel Aziz, Hind Mohd Ahmed, Emmanuel Stip, Dina Aly El-Gabry","doi":"10.1097/yic.0000000000000538","DOIUrl":"https://doi.org/10.1097/yic.0000000000000538","url":null,"abstract":"The risk of metabolic syndrome (MetS) has been attributed to antipsychotic use in psychiatric patients. To date, there is limited data on the relationship between antipsychotic polypharmacy and MetS in patients with schizophrenia, schizoaffective disorder and bipolar disorder. Therefore, we aimed to investigate the rate of MetS in patients with these disorders receiving antipsychotic monotherapy and polypharmacy. We conducted a cross-sectional study on patients seen between January 2017 and December 2020, collecting data on the class, type, route of administration and number of antipsychotics received. We used the American Association of Clinical Endocrinology criteria to diagnose MetS. We included 833 subjects of whom 573 (68.8%) received antipsychotic monotherapy and 260 (31.2%) received polypharmacy. Overall, 28.6% (N = 238) had MetS with no statistical difference between the two groups. Diastolic blood pressure and receiving olanzapine were significant predictors for developing MetS. In conclusion, our study found no significant difference in the rate of MetS between antipsychotic monotherapy and polypharmacy. A number of variables were significant predictors for MetS. Our findings were consistent with other studies and warrant the need for careful choice of antipsychotics and regular screening and management of abnormal metabolic parameters.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"12 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139920190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The bidirectional interaction between antidepressants and the gut microbiota: are there implications for treatment response? 抗抑郁药与肠道微生物群之间的双向作用：对治疗反应有影响吗？

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-02-06 DOI: 10.1097/YIC.0000000000000533

Gianluca Borgiani, Chiara Possidente, Chiara Fabbri, Vincenzo Oliva, Mirjam Bloemendaal, Alejandro Arias Vasquez, Ted G Dinan, Eduard Vieta, Marco Menchetti, Diana De Ronchi, Alessandro Serretti, Giuseppe Fanelli

{"title":"The bidirectional interaction between antidepressants and the gut microbiota: are there implications for treatment response?","authors":"Gianluca Borgiani, Chiara Possidente, Chiara Fabbri, Vincenzo Oliva, Mirjam Bloemendaal, Alejandro Arias Vasquez, Ted G Dinan, Eduard Vieta, Marco Menchetti, Diana De Ronchi, Alessandro Serretti, Giuseppe Fanelli","doi":"10.1097/YIC.0000000000000533","DOIUrl":"10.1097/YIC.0000000000000533","url":null,"abstract":"This review synthesizes the evidence on associations between antidepressant use and gut microbiota composition and function, exploring the microbiota's possible role in modulating antidepressant treatment outcomes. Antidepressants exert an influence on measures of gut microbial diversity. The most consistently reported differences were in β-diversity between those exposed to antidepressants and those not exposed, with longitudinal studies supporting a potential causal association. Compositional alterations in antidepressant users include an increase in the Bacteroidetes phylum, Christensenellaceae family, and Bacteroides and Clostridium genera, while a decrease was found in the Firmicutes phylum, Ruminococcaceae family, and Ruminococcus genus. In addition, antidepressants attenuate gut microbial differences between depressed and healthy individuals, modulate microbial serotonin transport, and influence microbiota's metabolic functions. These include lyxose degradation, peptidoglycan maturation, membrane transport, and methylerythritol phosphate pathways, alongside gamma-aminobutyric acid metabolism. Importantly, baseline increased α-diversity and abundance of the Roseburia and Faecalibacterium genera, in the Firmicutes phylum, are associated with antidepressant response, emerging as promising biomarkers. This review highlights the potential for gut microbiota as a predictor of treatment response and emphasizes the need for further research to elucidate the mechanisms underlying antidepressant-microbiota interactions. More homogeneous studies and standardized techniques are required to confirm these initial findings.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11594561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

No gender differences in the pharmacological emergency treatment of schizophrenia: results of a 21-year observation. 精神分裂症的药物急救治疗无性别差异:一项21年观察的结果

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-08-09 DOI: 10.1097/YIC.0000000000000495

Monika Edlinger, Stefanie Brettbacher, Timo Schurr, Nursen Yalcin-Siedentopf, Alex Hofer

{"title":"No gender differences in the pharmacological emergency treatment of schizophrenia: results of a 21-year observation.","authors":"Monika Edlinger, Stefanie Brettbacher, Timo Schurr, Nursen Yalcin-Siedentopf, Alex Hofer","doi":"10.1097/YIC.0000000000000495","DOIUrl":"10.1097/YIC.0000000000000495","url":null,"abstract":"Patients suffering from schizophrenia are at high risk for admission and treatment in locked units. This study investigated gender differences in the pharmacological emergency treatment of schizophrenia patients over a 21-year observation period. The current retrospective study was conducted at the Division of Psychiatry I of the Medical University Innsbruck. All adult patients (n = 845; 425 female) suffering from schizophrenia who were admitted involuntarily to one of the acute psychiatric units in the years 1997, 2002, 2007, 2012 and 2017 were included in the study. In the years mentioned above, 590 schizophrenia patients (297 men, 293 women) admitted to a locked unit received pharmacological emergency treatment. With the exception of clozapine which was more frequently administered to men no significant differences between men and women were found in terms of the choice, dosage, and type of application of medication (antipsychotics and benzodiazepines). Since most treatment guidelines for schizophrenia do not consider gender differences at all, it is not surprising that acute treatment is almost the same for men and women. However, in times when individualized therapies gain more and more importance, the consideration of sex differences should be part of new treatment concepts.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"36-41"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10316876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Possible genetic biomarker associated with antipsychotic-induced amenorrhea in female patients with schizophrenia. 女性精神分裂症患者抗精神病药物引起的闭经可能的遗传生物标志物。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-08-07 DOI: 10.1097/YIC.0000000000000501

Jung-Joon Moon, Ho-Sook Kim, Joo-Cheol Shim, Jung-Mee Ahn, Do-Un Jung, Dong-Jin Kim, Hye-Eun Jeong, Eun-Young Kim, Dong-Wook Jeon, Sung-Jin Kim, Jae-Gook Shin

{"title":"Possible genetic biomarker associated with antipsychotic-induced amenorrhea in female patients with schizophrenia.","authors":"Jung-Joon Moon, Ho-Sook Kim, Joo-Cheol Shim, Jung-Mee Ahn, Do-Un Jung, Dong-Jin Kim, Hye-Eun Jeong, Eun-Young Kim, Dong-Wook Jeon, Sung-Jin Kim, Jae-Gook Shin","doi":"10.1097/YIC.0000000000000501","DOIUrl":"10.1097/YIC.0000000000000501","url":null,"abstract":"This study explored the association of pharmacogenomics with antipsychotic-induced amenorrhea in female patients with schizophrenia. A total of 89 female schizophrenia patients aged 18-40 receiving consistent antipsychotics at a consistent dose for more than 3 months were enrolled in this study. Amenorrhea was defined as the absence of menstrual period for 3 months or three periods in a row. Serum levels of prolactin, estradiol, follicle-stimulating hormone, luteinizing hormone, and thyroid-stimulating hormone were measured and Cytochrome P450 2D6, dopamine receptor D2 ( DRD2 ) and estrogen receptor 1 were genotyped. Twenty-two patients with amenorrhea had higher prolactin levels and lower estradiol levels than those without amenorrhea (94.1 vs. 71.5 ng/ml for prolactin; P = 0.044 and 27.0 vs. 46.7 pg/ml for estradiol; P = 0.007, respectively). Multiple logistic regression analysis identified DRD2 -141C deletion [odds ratio (OR) = 1.71, 95% confidence interval (CI) = 1.01-4.17; P = 0.049] and drugs increasing prolactin levels (OR = 6.17, 95% CI = 1.28-29.64; P = 0.023) as significant covariates for antipsychotic-induced amenorrhea. This study suggests that DRD2 -141C deletion is associated with antipsychotic-induced amenorrhea although further studies are needed.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"29-35"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9945361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Microsampling for therapeutic drug monitoring in psychiatric practice. 精神病学实践中治疗药物监测的显微取样。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-08-16 DOI: 10.1097/YIC.0000000000000503

Michele Protti, Roberto Mandrioli, Laura Mercolini

引用次数: 1

Focus on antipsychotics and related therapeutic drug monitoring. 专注于抗精神病药物及相关治疗药物的监测。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-11-19 DOI: 10.1097/YIC.0000000000000523

Alessandro Serretti

引用次数: 0

Relationship between clinical efficacy and plasma concentration-dose ratio of risperidone in patients with schizophrenia. 精神分裂症患者利培酮的临床疗效与血浆浓度剂量比的关系。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-11-02 DOI: 10.1097/YIC.0000000000000490

Qiuying Chen, Jie Min, Haibo Yin, Wenying Xia, Yimin Shen, Ming Shu

{"title":"Relationship between clinical efficacy and plasma concentration-dose ratio of risperidone in patients with schizophrenia.","authors":"Qiuying Chen, Jie Min, Haibo Yin, Wenying Xia, Yimin Shen, Ming Shu","doi":"10.1097/YIC.0000000000000490","DOIUrl":"10.1097/YIC.0000000000000490","url":null,"abstract":"This study aimed to retrospectively explore the relationship between clinical efficacy and plasma concentration-dose ratio of risperidone (RIS) in 252 patients with schizophrenia taking RIS orally. After the same dose of RIS treatment, the plasma concentration of RIS/9-hydroxyrisperidone (9-OH-RIS), the total plasma concentration of RIS, and the ratio of the steady-state plasma concentration to the daily dose of the total active product (C/D) showed individual difference. The RIS plasma concentration was significantly higher in patients taking high doses than those taking lower doses ( P = 0.003). There was a statistically significant difference in C/D ratio between males and females ( P = 0.003). There were significant differences in ratio of C/D and the total plasma concentration of RIS between patients under 60 years and over 60 years ( P = 0.016; P = 0.005). Logistic regression analysis showed that the therapeutic effect and adverse reactions of RIS were correlated with the ratio of C/D in patients with schizophrenia ( P = 0.038; P < 0.001). It has been suggested that the importance of monitoring of the plasma concentration of RIS in patients with schizophrenia and the ratio of C/D may be used as the reference for RIS personalized treatment.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"17-22"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9954149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Capillary blood sampling for the determination of clozapine concentrations: analytical validation and patient experience. 毛细管血液取样测定氯氮平浓度:分析验证和患者经验。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-08-07 DOI: 10.1097/YIC.0000000000000494

Bianca D Breken, Koen P Grootens, Annemieke M Vermeulen Windsant-van den Tweel, Walter A Hermens, Hieronymus J Derijks

{"title":"Capillary blood sampling for the determination of clozapine concentrations: analytical validation and patient experience.","authors":"Bianca D Breken, Koen P Grootens, Annemieke M Vermeulen Windsant-van den Tweel, Walter A Hermens, Hieronymus J Derijks","doi":"10.1097/YIC.0000000000000494","DOIUrl":"10.1097/YIC.0000000000000494","url":null,"abstract":"Patients may be reluctant to start clozapine (CLZ) because of the frequent blood sampling needed for white blood cell monitoring, but also therapeutic drug monitoring of CLZ. Finger prick, instead of venepuncture, might lower the threshold to CLZ use. The aim of this study was to determine whether CLZ concentrations are the same in capillary and venous blood samples. Capillary blood was drawn by finger prick and collected in the Hem-Col tube. Paired capillary and venous blood samples were collected from inpatients and outpatients of a mental health institute. Patients were asked to rate pain, experience, and preference for blood sampling method. Passing-Bablok analysis of 40 paired samples showed that CLZ concentrations were statistically equal in capillary and venous samples {slope 0.96 [95% confidence interval (CI): 0.88-1.04], intercept -6.86 (95% CI: -30.75 to 24.13)}. Venepuncture was the preferred method based on the experience ( P = 0.009) and preference ( P = 0.043) items. In conclusion, CLZ concentrations were similar in venous and capillary blood samples. Venepuncture appeared to be preferred to finger prick for blood sampling. Our results emphasize the importance of consulting patients' individual preference for blood sampling method.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"23-28"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10326456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Differentiating the third generation of antipsychotics: a focus on lumateperone's similarities and differences. 区分第三代抗精神病药物：关注鲁马替培隆的异同。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-01-01 Epub Date: 2023-09-20 DOI: 10.1097/YIC.0000000000000510

Gloria M Munayco Maldonado, Thomas L Schwartz

{"title":"Differentiating the third generation of antipsychotics: a focus on lumateperone's similarities and differences.","authors":"Gloria M Munayco Maldonado, Thomas L Schwartz","doi":"10.1097/YIC.0000000000000510","DOIUrl":"10.1097/YIC.0000000000000510","url":null,"abstract":"The development of atypical antipsychotics has evolved to include newer pharmacodynamic properties. Lumateperone, aripiprazole, brexpiprazole, and cariprazine are all dopamine-2 receptor partial agonists with varying receptor affinities. This review aims to compare the clinical and pharmacodynamic differences among these four atypical antipsychotics, all of which are unique when compared to first- and second-generation antipsychotics. For consideration is further delineating these agents as being third-generation antipsychotics. PubMed searches were conducted to compile preclinical and clinical studies derived from animal models and human subjects. Information gathered included pharmacological mechanisms, clinical efficacy, future-oriented clinical approaches, and adverse effects. Efficacy for the shared indications of these drugs seems comparable. Differences among these drugs lie more in their adverse effect profiles. For example, lumateperone was found to have the lowest rate of weight gain while brexpiprazole was found to have the highest rate of weight gain associated with increased appetite. Aripiprazole had the lowest rates of extrapyramidal symptoms not including akathisia while cariprazine had the highest. All four agents reviewed have a variety of receptor affinities, which likely generates a variety of different adverse effects. This suggests that in any given patient, clinicians may see differential clinical effects.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"4-16"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41118992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Diabetes mellitus in patients with chronic bipolar disorder: prevalence, clinical correlates and relationship with homocysteine. 慢性双相情感障碍患者的糖尿病:患病率、临床相关性及与同型半胱氨酸的关系

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2023-11-20 DOI: 10.1097/YIC.0000000000000504

Li Mu, Dachun Chen, Meihong Xiu, Huixia Zhou, Dongmei Wang, Xiang-Yang Zhang

{"title":"Diabetes mellitus in patients with chronic bipolar disorder: prevalence, clinical correlates and relationship with homocysteine.","authors":"Li Mu, Dachun Chen, Meihong Xiu, Huixia Zhou, Dongmei Wang, Xiang-Yang Zhang","doi":"10.1097/YIC.0000000000000504","DOIUrl":"10.1097/YIC.0000000000000504","url":null,"abstract":"Comorbid diabetes mellitus in patients with bipolar disorder may contribute to increased morbidity and mortality. To determine the prevalence of diabetes mellitus in bipolar disorder patients and its clinico-demographic and homocysteine correlates, we conducted a cross-sectional survey of 195 bipolar disorder inpatients. They received questionnaires, clinical measurements and laboratory tests to assess demographic characteristics, anthropometric variables, clinical variables and plasma homocysteine levels. The prevalence of diabetes mellitus (including type 1, type 2 and special types) in Chinese bipolar disorder patients was 14.9%. Analysis of variance or chi-square test showed that compared with non-diabetic bipolar disorder patients, diabetic bipolar disorder patients were older, more often married, had a longer duration of disease, took less olanzapine and had a higher frequency of hypertension. However, there were no significant differences in body mass index (BMI) and homocysteine levels between diabetic and non-diabetic bipolar disorder patients. Logistic regression analysis showed that marital status and duration of disease were independently associated with diabetes mellitus in patients with bipolar disorder after controlling for age, use of olanzapine, presence of hypertension, BMI and homocysteine levels. These findings shed light on the clinico-demographic correlates of the increased prevalence of diabetes mellitus in bipolar disorder patients, rather than the correlation with some metabolic risk factors.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0